Holen Sie sich die Stockscreener-App
7.84
5.66%
-0.47
Handel nachbörslich:
7.84
Schlusskurs vom Vortag:
$8.31
Offen:
$8.4
24-Stunden-Volumen:
31,463
Relative Volume:
0.79
Marktkapitalisierung:
$97.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-33.82M
KGV:
-0.3064
EPS:
-25.5891
Netto-Cashflow:
$-66.04M
1W Leistung:
-4.85%
1M Leistung:
-12.11%
6M Leistung:
+102.58%
1J Leistung:
+88.92%
1-Tages-Spanne:
$7.6859
$8.64
1-Wochen-Bereich:
$7.6859
$8.89
52-Wochen-Spanne:
$3.3419
$11.45
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Firmenname
Elicio Therapeutics Inc
Sektor
Branche
Telefon
(857) 209-0050
Adresse
451 D STREET, 5TH FLOOR, BOSTON
Vergleichen Sie ELTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
7.84 | 97.51M | 0 | -33.82M | -66.04M | -25.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Elicio Therapeutics Inc Aktie (ELTX) Neueste Nachrichten
How to Take Advantage of moves in (ELTX) - Stock Traders Daily
Clal Biotech Completes Elicio Divestment and Initiates Loan Repayment - TipRanks
Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Why Elicio Therapeutics Inc (ELTX) Is Skyrocketing So Far In 2025 - Insider Monkey
Elicio Therapeutics secures $10 million in direct offering - MSN
Elicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 Data - Seeking Alpha
Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
Elicio Therapeutics Raises Fresh Capital: $10M Strategic Funding Deal Includes Bonus Warrants - StockTitan
Elicio Therapeutics Advances with New Clinical Updates - TipRanks
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
FDA Supports Registrational Strategy for ELI-002 in KRAS-Driven Cancers - Targeted Oncology
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy - The Manila Times
Elicio Therapeutics Secures FDA Support for ELI-002 Cancer Therapy Phase 3 Strategy - StockTitan
(ELTX) Investment Report - Stock Traders Daily
Why INNOVATE Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket - Benzinga
Serina Therapeutics Appoints Former Jazz Pharmaceuticals Finance Executive Karen Wilson to Board - StockTitan
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
Trading (ELTX) With Integrated Risk Controls - Stock Traders Daily
Elicio Therapeutics Advances ELI-002 and Secures Funding - Yahoo Finance
Elicio reports promising cancer vaccine trial results By Investing.com - Investing.com Canada
Elicio Therapeutics Presents Updated Results from ELI-002 - GlobeNewswire
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO - The Bakersfield Californian
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024 - Business Upturn
(ELTX) Investment Analysis and Advice - Stock Traders Daily
Elicio completes phase 2 enrollment for cancer vaccine By Investing.com - Investing.com Canada
Elicio completes phase 2 enrollment for cancer vaccine - Investing.com India
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment - GlobeNewswire
Elicio Therapeutics Completes Phase 2 Trial Enrollment for Pancreatic Cancer Treatment - StockTitan
SEC Form 424B3 filed by Elicio Therapeutics Inc. - Quantisnow
Elicio Therapeutics: Q3 Earnings Snapshot - mySA
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Elicio Therapeutics adjourns annual meeting due to lack of quorum - Investing.com
Elicio reports promising Phase 1 cancer vaccine trial results - Investing.com India
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting - GlobeNewswire
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study - The Bakersfield Californian
Elicio Therapeutics adjourns annual meeting due to lack of quorum By Investing.com - Investing.com UK
Jones Trading Initiates Coverage of Elicio Therapeutics (ELTX) with Buy Recommendation - MSN
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit - The Manila Times
Elicio Therapeutics to Present Clinical Data at the Society - GlobeNewswire
All You Need to Know About Elicio Therapeutics (ELTX) Rating Upgrade to Strong Buy - Yahoo Finance
Elicio Therapeutics announces new CFO and accounting officer By Investing.com - Investing.com Australia
Elicio Therapeutics announces new CFO and accounting officer - Investing.com
Elicio Therapeutics reports inducement grants - TipRanks
Elicio Therapeutics Reports Inducement Grants - GlobeNewswire
Finanzdaten der Elicio Therapeutics Inc-Aktie (ELTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.45%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):